JMW-3B3 Antibody Targeting Soluble CTLA-4
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for modulating the adaptive immune response, particularly in relation to T cell activation, are not selective enough and often have broad, non-specific effects, with existing antibodies targeting CTLA-4 not distinguishing between soluble and membrane-bound forms, limiting their therapeutic potential in diseases such as cancer and autoimmune disorders.
Innovation Solution
Development of a monoclonal antibody, JMW-3B3, specifically targeting the soluble form of CTLA-4 (sCTLA-4), which binds with high affinity to a unique epitope, allowing for selective modulation of antigen-specific immune responses without affecting full-length CTLA-4 function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing antibodies targeting CTLA-4 are used, then T cell activation can be modulated, but the antibodies cannot distinguish between soluble and membrane-bound forms, causing non-specific effects
Solution Approach 1:
The invention segments the CTLA-4 target into two distinct forms: soluble CTLA-4 (sCTLA-4) and membrane-bound CTLA-4. By developing antibodies that specifically recognize only the soluble form (such as the JMW-3B3 antibody), the patent enables selective modulation of immune responses without affecting membrane-bound CTLA-4 function. This segmentation resolves the contradiction by allowing precise targeting of one form while preserving the function of the other.
Solution Approach 2:
The invention applies local quality by creating antibodies with differentiated binding specificities - some antibodies (like JMW-3B3) bind specifically to soluble CTLA-4, while others can bind both forms. This allows tailored therapeutic approaches where the antibody's binding profile can be matched to the desired therapeutic outcome, resolving the contradiction between specificity and versatility.
2Reliability
If broad immune modulation is achieved, then therapeutic effect is enhanced, but off-target effects increase
Solution Approach 1:
The invention extracts the soluble form of CTLA-4 as a distinct therapeutic target from the broader CTLA-4 system. By developing antibodies that specifically recognize and bind only to soluble CTLA-4 (extracted from the mixture of CTLA-4 forms), the patent enables selective immune modulation that achieves therapeutic efficacy while minimizing off-target effects on membrane-bound CTLA-4 and other immune pathways.
3Measurement precision
If soluble CTLA-4 is specifically targeted, then selectivity is improved, but the complexity of antibody development increases
Solution Approach 1:
The invention applies preliminary action by first isolating and characterizing the soluble CTLA-4 form, identifying its unique epitopes, and then using this knowledge to guide the development of selective antibodies. This preliminary characterization work simplifies subsequent antibody development by providing clear targets and validation methods, reducing the overall complexity despite the increased selectivity requirements.
Data Source
AI summary
The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.